Evolus (EOLS) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evolus (EOLS) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 4.8% versus a loss of 27.9%. Over five years, EOLS leads with a +14.4% price change compared with -92.6% for LYEL. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -41.0%).
Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | LYEL |
|---|---|---|
| Share price | $6.52 | $13.80 |
| Market cap | $431.55M | $441.82M |
| 1-day change | -6.86% | +1.62% |
| YTD return | -1.95% | -55.17% |
| 1-year return | -4.82% | -27.86% |
| 5-year return | +14.39% | -92.59% |
| Forward P/E | 22.68 | — |
| EPS (TTM) | $-0.48 | $-12.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $297.18M | $36.00K |
| Revenue growth (YoY) | +11.61% | -40.98% |
| Net income (latest FY) | $-51.64M | $-274.45M |
| Gross margin | 66.33% | — |
| Operating margin | -10.99% | -748344.44% |
| Net margin | -17.38% | -762355.56% |
| 52-week high | $9.31 | $45.00 |
| 52-week low | $3.86 | $7.20 |
| Distance from 52-week high | -29.97% | -69.33% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +136.20% | +172.68% |
| Average volume | 925.77K | 174.76K |
| Shares outstanding | 66.19M | 32.02M |
| Employees | 365 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed LYEL by 23.0 percentage points over the past year.
- Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- Evolus grew revenue faster in its latest fiscal year (+11.61% vs -40.98%).
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
EOLS vs LYEL FAQ
Which is bigger, Evolus or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $431.55M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or LYEL?
EOLS returned -4.82% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.